Brennan Aoife 4

What Happened

• Brennan Aoife, a director of Xilio Therapeutics (XLO), received a grant of derivative securities covering 5,000 shares on June 11, 2026. The filing reports the acquisition price as $0.00. The award is identified in the footnote as an option that will vest 100% on the earlier of June 11, 2027 or the issuer’s next annual meeting of stockholders, subject to continued service.

Key Details

• Transaction date: 2026-06-11; filing date: 2026-06-12 (appears timely).
• Reported acquisition: 5,000 derivative securities (option) at $0.00.
• Shares owned after transaction: not specified in the filing.
• Footnote: Option vests 100% on earlier of (i) 6/11/2027 or (ii) the issuer’s next annual meeting, subject to continued service.
• No indication of a sale, exercise, 10b5-1 plan, or tax-withholding in this filing.

Context

• This is a grant/award (not an open-market purchase or sale). For retail investors, grants signal future potential ownership if the award vests and is exercised; they do not represent an immediate cash transaction or sale.
• The filing lists the instrument as a derivative (option) and a $0.00 acquisition — review the company’s proxy or grant agreement for details on exercise price and terms if you need more clarity.